Wolfe Research initiates West Pharmaceutical Services coverage with $375 price target
The brokerage applies a 40 times multiple to 2027 earnings, aligning with the injectable packaging specialist’s 15-year trading history and premium to the broader market.
Wolfe Research has initiated coverage of West Pharmaceutical Services Inc (WST) with an Outperform rating and a price target of $375. The analyst firm released the note on 31 May, grounding its valuation in the company’s underlying business fundamentals and historical trading metrics.
The $375 target implies a valuation of 40 times projected earnings per share for 2027. Wolfe Research noted that this multiple is consistent with West Pharmaceutical’s historical trading range, which has averaged approximately 40 times earnings over the past 15 years. The firm argued that this historical precedent supports the current valuation outlook.
Beyond the earnings multiple, the brokerage highlighted the stock’s consistent premium to the broader market. West Pharmaceutical has historically traded at a valuation more than 100 per cent higher than the S&P 500 and 75 per cent above its sector peers. Wolfe Research indicated that this premium reflects the company’s strong position within the pharmaceutical supply chain.
West Pharmaceutical Services manufactures critical packaging and delivery systems for injectable medicines. Its product portfolio includes rubber stoppers, seals, plungers, prefilled syringes, and self-injection devices. These components are essential for pharmaceutical and biotechnology companies to safely store and administer drugs.
The stock has demonstrated significant momentum in recent trading sessions. WST shares are up approximately 14 per cent year-to-date and have gained nearly 50 per cent over the past 12 months. The company is also recognised by billionaire Bill Gates as one of the best stocks to buy, adding to its profile among institutional investors.
